Bilayer Levocarnitine Tablet Structure for Hygroscopicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for levocarnitine and trimetazidine tablets suffer from stability issues due to impurities from excipients like lactose, copovidone, and microcrystalline cellulose, leading to uneven drug content and increased costs, without effectively addressing hygroscopicity and stability concerns.
Innovation Solution
A bilayer tablet design is implemented, with levocarnitine and trimetazidine dihydrochloride in separate layers, using specific excipients like povidone, microcrystalline cellulose, and mannitol, and a controlled granulation process to minimize contact with air and impurities, ensuring uniform distribution and improved stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If levocarnitine and trimetazidine are mixed and granulated together with starch and lactose, then a compound tablet can be prepared, but the content uniformity of the main drug deteriorates and impurity levels increase
Solution Approach 1:
The patent divides the tablet into two separate layers: a levocarnitine layer and a trimetazidine layer. Each layer is granulated separately with its own excipients, then compressed together. This segmentation prevents mixing errors and ensures uniform distribution of each drug independently, resolving the content uniformity issue while maintaining manufacturing efficiency.
2Manufacturing precision
If levocarnitine and trimetazidine are granulated separately and then mixed, then drug content uniformity improves, but the use of excipients increases significantly and costs rise
Solution Approach 1:
The patent applies local quality by assigning different excipient compositions to different layers. The levocarnitine layer uses starch and lactose as excipients, while the trimetazidine layer uses different excipients. This allows each layer to have optimized excipient content for its specific drug, reducing overall excipient usage compared to a single-layer approach while maintaining content uniformity.
3Ease of manufacture
If traditional excipients like lactose, copovidone, and microcrystalline cellulose are used, then tablet formulation is straightforward, but stability deteriorates due to impurities and reactions with active pharmaceutical ingredients
Solution Approach 1:
The patent extracts problematic excipients (lactose, copovidone, microcrystalline cellulose) that cause stability issues and replaces them with more stable alternatives. By removing these harmful components from the formulation, the patent eliminates the sources of impurity generation and degradation reactions, thereby improving tablet stability while maintaining ease of manufacture.
4Ease of manufacture
If levocarnitine is exposed to air during preparation, then granulation process is simple, but hygroscopicity increases significantly
Solution Approach 1:
The patent uses a layered tablet structure where the levocarnitine layer is covered by the trimetazidine layer, creating a protective barrier that limits air exposure. This physical protection reduces hygroscopicity of the levocarnitine without complicating the granulation process, as each layer is still granulated separately using standard procedures.
Data Source
AI summary
Disclosed is a levocarnitine and trimetazidine bilayer tablet. The present disclosure adopts a bilayer structure of the levocarnitine and trimetazidine dihydrochloride, and a contact area between the levocarnitine layer and the air can be greatly reduced by covering one side of a surface of the levocarnitine layer with the trimetazidine dihydrochloride layer, such that the problem of hygroscopicity of the levocarnitine layer can be effectively inhibited, and the effective amount of the drug is increased. Moreover, the preparation process in the present disclosure is easy to operate and suitable for actual production and use, as well as is capable of solving the problem of content uniformity well, and the stability of the bilayer tablet is effectively improved.